

EDITORS-IN-CHIEF

Michael F. Drummond, MCom, DPhil
University of York

C. Daniel Mullins, PhD
University of Maryland

EDITORIAL STAFF

Lyn Beamesderfer
Director, Publications

Detra Davis
Senior Manager, Publications

ISPOR CORPORATE OFFICERS

Nancy S. Berg
Chief Executive Officer/Executive Director

Richard J. Willke, PhD
Chief Science Officer

Laura T. Pizzi, PharmD, MPH
Associate Chief Science Officer

Betsy Lane
Director and Chief Marketing &
Communications Officer

Sue Capon
Chief Operations Officer



CONTENTS

THEMED SECTION: THE PATIENT JOURNEY

- 1 Patient-Reported Satisfaction, Experiences, and Preferences: Same but Different?**
Axel Mühlbacher and Elly Stolk
The authors summarize key issues in the development and use of patient-reported experience measures that capture patient satisfaction and perception of products and services.
- 4 Patient Expectations About Palliative Treatment for Symptomatic Spinal Metastases: A Qualitative Study**
Roxanne Gal, Raphaële Charest-Morin, Jorrit-Jan Verlaan, Charles G. Fisher, Hester Wessels, Helena M. Verkooijen, and Anne L. Versteeg
Patients felt they were not or only minimally informed about expected outcomes after surgery and/or radiation therapy for symptomatic spinal metastases.
- 10 Enhancing Patient Centricity of Real-World Data Research: An Exploratory Analysis Using the Patient Experience Mapping Toolbox**
Elisabeth M. Oehrlein, Mehmet Burcu, Silke Schoch, and Laura Elisabeth Gressler
This paper examines how researchers could leverage qualitative patient experience data captured through the Patient Experience Mapping Toolbox to guide real-world data research designs.
- 18 A Data-Driven Approach to Support the Understanding and Improvement of Patients' Journeys: A Case Study Using Electronic Health Records of an Emergency Department**
Farhood Rismanchian, Sara Hosseinzadeh Kassani, Seyed Mahdi Shavarani, and Young Hoon Lee
A process mining-based patient journey modeling approach supports an understanding of patient experiences and performance improvement of healthcare delivery processes.
- 28 Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process**
Elisabeth M. Oehrlein, Silke Schoch, Mehmet Burcu, Julia F. McBeth, Jennifer Bright, Chris L. Pashos, Richard Willke, T. Rosie Love, T. Joseph Mattingly, II, and Eleanor M. Peretto, on behalf of the Patient-Centered Real-World Evidence Working Group
This article describes how patient experiences/insights data can be incorporated into the design, conduct, and translation of real-world research that reflects patients' lived experience.

Value in Health CONTENTS (continued)

39 Patient and Caregiver Experience Decision Factors in Treatment Decision Making: Results of a Systematic Literature Review of Multiple Myeloma Decision Aids

Mimi Choon-Quinones, Dirk Hose, Zoltán Kaló, Tamás Zelei, Jean-Luc Harousseau, Brian Durie, Paul Keown, Mike Barnett, and Ivetta Jakab

The authors examine the feasibility of current decision aids in guiding shared decision making in multiple myeloma.

BRIEF REPORT

50 Test-Retest Reliability of EQ-5D-Y-3L Best-Worst Scaling Choices of Adolescents and Adults

Xiuqin Xiong, Kim Dalziel, Li Huang, and Oliver Rivero-Arias

Best-worst scaling is a reliable elicitation technique to value EQ-5D-Y-3L health states in both adolescents and adults.

55 Assessment of the Social Security Administration Death Master File for Comparative Analysis Studies of Peripheral Vascular Devices

Eric A. Secemsky, Eric Barrette, Lindsay Bockstedt, and Robert W. Yeh

The authors evaluated whether analyses evaluating differences in mortality risk between peripheral vascular device interventions are affected by underreporting of deaths in the Social Security Administration Death Master File.

COMMENTARY

60 Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges

Aurelie Meunier, Louise Longworth, Stacey Kowal, Sreeram Ramagopalan, James Love-Koh, and Susan Griffin

The authors describe the data requirements to conduct distributional cost-effectiveness analysis and key actions to improve the evidence base to build robust analysis for decision making.

COMPARATIVE-EFFECTIVENESS RESEARCH/HTA

64 Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Sarah Smith, Fernando Albuquerque de Almeida, Monica Inês, Laura Iadeluca, and Miranda Cooper

The results of indirect comparisons suggest that lorlatinib leads to longer overall and progression-free survival for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer than chemotherapy.

Mission Statement

As the official journal of ISPOR, Value in Health provides a forum for researchers, healthcare decision makers, and policy makers to apply health economics and outcomes research to healthcare decisions.

Value in Health CONTENTS (continued)

ECONOMIC EVALUATION

- 71 Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer**
Martijn J.H.G. Simons, Carin A. Uyl-de Groot, Valesca P. Retèl, Joanne M. Mankor, Bram L.T. Ramaekers, Manuela A. Joore, and Wim H. van Harten
Scenarios of possible futures of whole-genome sequencing as a diagnostic test in oncology were modeled to analyze expected costs, effects, and impact of uncertainty.
- 81 Cost-Effectiveness of a Specialized Breathlessness Service Versus Usual Care for Patients With Advanced Diseases**
Hildegard Seidl, Michaela Schunk, Lien Le, Zulfiya Syunyaeva, Sabine Streitwieser, Ursula Berger, Ulrich Mansmann, Boglarka Lilla Szentes, Claudia Bausewein, and Larissa Schwarzkopf
The specialized breathlessness service is an effective and low-cost intervention for patients with advanced disease improving disease-specific and generic health-related quality of life.

METHODOLOGY

- 91 The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data**
Marcel H. Schöttler, Friso B. Coerts, Maarten J. Postma, Cornelis Boersma, and Mark H. Rozenbaum
The implementation of dynamic real-world pricing data could potentially estimate cost-effectiveness ratios more representative compared with the conventional approach of assuming constant drug prices.
- 99 For Me or for My Relatives? Approximating Self-Protection and Local Altruistic Motivations Underlying Preferences for Public Health Policies Using Risk Perception Metrics**
Aemiro Melkamu Daniel, Niek Mouter, and Caspar G. Chorus
The authors present an indirect way to uncover selfish and altruistic motivations behind support for healthcare policies based on risk perception metrics.



ISPOR

Improving healthcare decisions

Value in Health CONTENTS (continued)

PREFERENCE-BASED ASSESSMENTS

104 Heterogeneous Preferences for Colorectal Cancer Screening in Germany: Results of a Discrete Choice Experiment

Melanie Brinkmann, Leonie Diedrich, Melissa Hemmerling, Christian Krauth, Bernt-Peter Robra, Jona T. Stahmeyer, and Maren Dreier

This discrete choice experiment on characteristics of colorectal cancer screening tests revealed significant heterogeneous and partly unexpected preferences among German insurees that need further research.

115 Valuing Health Gain from Composite Response Endpoints for Multisystem Diseases

Sean P. Gavan, Ian N. Bruce, and Katherine Payne, on behalf of the MASTERPLANS Consortium

Valuing the health gain associated with composite response endpoints will improve their usefulness for health technology assessment, economic evaluation, and decision making.

SYSTEMATIC LITERATURE REVIEW

123 Measuring, Analyzing, and Presenting Work Productivity Loss in Randomized Controlled Trials: A Scoping Review

Wei Zhang, Paige Tocher, Jacynthe L'Heureux, Julie Sou, and Huiying Sun

There is a lack of consensus on how to measure, analyze, and present work productivity loss outcomes in recent randomized controlled trials.

138 Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review

Antonio Oly de Labry-Lima, Angela Ponce-Polo, Leticia García-Mochón, Marta Ortega-Ortega, Daniel Pérez-Troncoso, and David Epstein

This systematic review indicated that advanced therapy medical products are found in 3 of the 4 quadrants of the cost-effectiveness plane.



ISPOR

Improving healthcare decisions